Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children

We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: adults, HPIV-1–seropositive children, and HPIV-1–seronegative children, the targe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the Pediatric Infectious Diseases Society 2015-12, Vol.4 (4), p.e143-e146
Hauptverfasser:	Karron, Ruth A., San Mateo, Jocelyn, Thumar, Bhagvanji, Schaap-Nutt, Anne, Buchholz, Ursula J., Schmidt, Alexander C., Bartlett, Emmalene J., Murphy, Brian R., Collins, Peter L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Viral - blood Child, Preschool Double-Blind Method ELECTRONIC ARTICLES Humans Infant Parainfluenza Vaccines - therapeutic use Parainfluenza Virus 1, Human Paramyxoviridae Infections - epidemiology Paramyxoviridae Infections - prevention & control Vaccines, Attenuated - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We conducted a phase I clinical trial (clinicaltrials.gov identifier, NCT00641017) of the experimental live-attenuated human parainfluenza virus type 1 (HPIV-1) vaccine rHPIV-1/84/del 170/942A sequentially in 3 groups: adults, HPIV-1–seropositive children, and HPIV-1–seronegative children, the target population for vaccination. rHPIV-1/84/del 170/942A was appropriately restricted in replication in adults and HPIV-1–seropositive children but was overattenuated (ie, insufficiently infectious and immunogenic) for HPIV-1–seronegative children.
ISSN:	2048-7193 2048-7207
DOI:	10.1093/jpids/piu104